{"product_id":"recombinant-human-il-6-protein-bhp22200027","title":"Recombinant Human IL-6 Protein","description":"\u003cdiv class=\"bhp-desc\"\u003e\n\u003cstyle\u003e.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}.bhp-desc p{margin:0 0 12px}.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}.bhp-desc .bhp-app-wrap{overflow-x:auto}.bhp-desc .bhp-app-table{width:100%;border-collapse:collapse;margin:12px 0 18px;font-size:14px}.bhp-desc .bhp-app-table th{background:#e8f0fb;color:#003366;text-align:left;padding:8px 10px;border:1px solid #ccd9f0;vertical-align:top}.bhp-desc .bhp-app-table td{padding:8px 10px;border:1px solid #ccd9f0;vertical-align:top}.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\u003c\/style\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eRecombinant Protein · Interleukin\u003c\/span\u003e\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eRecombinant Human IL-6 Protein\u003c\/strong\u003e is a full-length, glycosylated monomer expressed in \u003cstrong\u003ehuman cells\u003c\/strong\u003e. It is manufactured in an animal-free, xeno-free and tag-free format and supplied lyophilized without carrier protein, at \u0026gt;95% purity by SDS-PAGE and endotoxin \u0026lt;0.5 EU\/µg.\u003c\/p\u003e\n\u003cp\u003eTypical research uses include JAK\/STAT3 activation through IL-6R and gp130, the late stages of B-cell maturation into antibody-secreting cells, chosen hematopoietic and myeloid differentiation protocols, and models of acute-phase and inflammatory responses. Expression in human cells supports mammalian glycosylation, activity is confirmed by TF-1 cell proliferation, and one peer-reviewed study reports the use of this IL-6.\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eExpression system: Human cells · Tag-free · Animal-free\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eScientific Background\u003c\/h2\u003e\n\u003cp\u003eIL-6 is a pleiotropic, glycosylated cytokine produced by immune and stromal cell types. It binds membrane-bound or soluble IL-6R, forms a complex with gp130 and activates JAK\/STAT3, MAPK and PI3K pathways.\u003c\/p\u003e\n\u003cp\u003eIts roles span B-cell maturation and other immune-cell differentiation steps, the acute-phase response, hematopoietic progenitor biology and inflammatory programs that differ between tissues. Because it can act through both classical signaling and trans-signaling, experiments should distinguish the two; the outcome depends on IL-6R and soluble receptor availability, gp130, cell state, dose and exposure time.\u003c\/p\u003e\n\u003ch2\u003eResearch Applications\u003c\/h2\u003e\n\u003cp\u003eIL-6 is used in signaling, immune-cell and hematopoietic research, and as a defined stimulus for TF-1 bioassays. The table summarizes typical workflow placement; it is a planning guide, not a universal protocol.\u003c\/p\u003e\n\u003cdiv class=\"bhp-app-wrap\"\u003e\u003ctable class=\"bhp-app-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRole of IL-6\u003c\/th\u003e\n\u003cth\u003eCompanion signals and context\u003c\/th\u003e\n\u003cth\u003eSuggested readouts\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTF-1 bioassay\u003c\/td\u003e\n\u003ctd\u003eDose-dependent proliferation\u003c\/td\u003e\n\u003ctd\u003eDefined assay medium\u003c\/td\u003e\n\u003ctd\u003eProliferation and relative potency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eB-cell study\u003c\/td\u003e\n\u003ctd\u003eDifferentiation support\u003c\/td\u003e\n\u003ctd\u003eActivation and companion cytokines\u003c\/td\u003e\n\u003ctd\u003eCD38, CD138, immunoglobulin secretion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHepatocyte response\u003c\/td\u003e\n\u003ctd\u003eAcute-phase signaling\u003c\/td\u003e\n\u003ctd\u003eTime course and receptor context\u003c\/td\u003e\n\u003ctd\u003epSTAT3, CRP, SAA genes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyeloid\/DC workflow\u003c\/td\u003e\n\u003ctd\u003eMaturation-associated signal\u003c\/td\u003e\n\u003ctd\u003eGM-CSF\/IL-4 and maturation cocktail\u003c\/td\u003e\n\u003ctd\u003ePhenotype, cytokines, antigen presentation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003ePlanning considerations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eConfirm the responsive cell stage and receptor context, including membrane IL-6R versus soluble IL-6R.\u003c\/li\u003e\n\u003cli\u003eUse a published or internally validated protocol as the starting point and optimize the dose range in the chosen model.\u003c\/li\u003e\n\u003cli\u003eControl timing, medium, matrix and companion factors, and include vehicle\/no-factor and pathway-response controls.\u003c\/li\u003e\n\u003cli\u003eMeasure phenotype and function rather than cell number alone. No EC50 or universal working concentration is published.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eProtein Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eIL-6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlternative names\u003c\/th\u003e\n\u003ctd\u003eInterleukin-6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSpecies\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eExpression system\u003c\/th\u003e\n\u003ctd\u003eHuman cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStructure\u003c\/th\u003e\n\u003ctd\u003eGlycosylated monomer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eProtein family\u003c\/th\u003e\n\u003ctd\u003eInterleukin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eExpression region\u003c\/th\u003e\n\u003ctd\u003eFull length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eTag\u003c\/th\u003e\n\u003ctd\u003eTag-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAnimal origin\u003c\/th\u003e\n\u003ctd\u003eAnimal-free \/ xeno-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecular weight\u003c\/th\u003e\n\u003ctd\u003e26–30 kDa. Refer to the lot-specific Certificate of Analysis (CoA) for lot data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e\u0026gt;95% by SDS-PAGE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eEndotoxin level\u003c\/th\u003e\n\u003ctd\u003e\u0026lt;0.5 EU\/µg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eLyophilized from a 0.2 µm-filtered solution in PBS without carrier protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eForm\u003c\/th\u003e\n\u003ctd\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eBiological activity\u003c\/th\u003e\n\u003ctd\u003eStimulation of human TF-1 cell proliferation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eApplications\u003c\/th\u003e\n\u003ctd\u003eStem Cell Differentiation, Immunotherapy, Cell Signaling Studies, Cell Proliferation, Hematopoietic Differentiation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eBiological Activity \u0026amp; Quality Control\u003c\/h2\u003e\n\u003cp\u003eBiological activity is evaluated by stimulation of human TF-1 cell proliferation.\u003c\/p\u003e\n\u003cp\u003eLot-specific activity and purity data are provided on the Certificate of Analysis (CoA), available from BioHippo on request.\u003c\/p\u003e\n\u003ch2\u003eReconstitution\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eBriefly centrifuge the vial before opening.\u003c\/li\u003e\n\u003cli\u003eReconstitute in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin.\u003c\/li\u003e\n\u003cli\u003eMix gently and prepare single-use aliquots.\u003c\/li\u003e\n\u003cli\u003eAvoid repeated freeze–thaw cycles; a manual-defrost freezer is recommended.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eStorage \u0026amp; Shipping\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eAs supplied: −20°C to −80°C for up to 12 months from receipt. After reconstitution: 2°C to 8°C for up to 1 month, or −20°C to −80°C for up to 3 months, under sterile conditions. Avoid repeated freeze–thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003ePlease contact us to confirm shipping conditions for this product.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eSelected References\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eYasukawa K, Hirano T, Watanabe Y, et al. (1987) Structure and expression of human B cell stimulatory factor-2 (BSF-2\/IL-6) gene. EMBO J 6:2939-2945. \u003ca href=\"https:\/\/doi.org\/10.1002\/j.1460-2075.1987.tb02598.x\" target=\"_blank\" rel=\"noopener\"\u003e10.1002\/j.1460-2075.1987.tb02598.x\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eTanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6:a016295. \u003ca href=\"https:\/\/doi.org\/10.1101\/cshperspect.a016295\" target=\"_blank\" rel=\"noopener\"\u003e10.1101\/cshperspect.a016295\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eHunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16:448-457. \u003ca href=\"https:\/\/doi.org\/10.1038\/ni.3153\" target=\"_blank\" rel=\"noopener\"\u003e10.1038\/ni.3153\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\u003cp style=\"margin:0\"\u003eHandle as a laboratory reagent and consult the linked SDS before use. Avoid repeated freeze–thaw cycles of the reconstituted protein.\u003c\/p\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cem\u003eFor research use only. Not for diagnostic or therapeutic use.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"StemImmune LLC","offers":[{"title":"10 ug","offer_id":67641423429997,"sku":"HIM-I6-0010","price":108.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":67641434308973,"sku":"HIM-I6-0100","price":809.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/IL6_3-500x500.png?v=1791572848","url":"https:\/\/www.ebiohippo.com\/products\/recombinant-human-il-6-protein-bhp22200027","provider":"BioHippo","version":"1.0","type":"link"}